查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2038671

2026 年至 2035 年植入式心臟節律器的市場機會、成長要素、產業趨勢分析與預測。

Implantable Pacemakers Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2025年全球植入式心臟節律器市場價值53億美元，預計2035年將以4.8%的複合年成長率成長至83億美元。

植入式心臟節律器市場-IMG1

由於心血管疾病負擔日益加重，以及全球醫療系統中微創心血管手術的普及，該市場正在不斷擴張。對先進心臟節律管理解決方案的需求不斷成長，加上極具吸引力的醫保報銷政策，進一步推動了市場成長。植入式心臟心律調節器是醫療設備，旨在透過輸送可控電脈衝來調節異常心律並維持穩定的心率。這些裝置透過持續監測心臟的電活動並在發生心律不整時進行干預，從而確保有效的節律糾正。心房顫動和心搏過緩率不斷上升與老化、缺乏運動、肥胖、糖尿病和不良飲食習慣密切相關，而這些因素在全球範圍內都在增加。人口老化也是需求的主要促進因素，與老齡化相關的傳導障礙，例如房室傳導阻滯和病竇症候群，變得越來越常見。隨著預期壽命的延長，對長期心率節律管理解決方案的需求預計將保持強勁，從而支撐市場的持續成長。

市場範圍
開始年份 2025
預測期 2026-2035
上市時的市場規模 53億美元
預測金額 83億美元
複合年成長率 4.8%

到2025年，雙腔心律調節器市佔率將達到78.7%。此細分市場的主導地位源自於其維持房室同步的能力，與單腔心律調節器相比，雙腔心律調節器能夠提高心臟功能效率，改善患者預後。臨床上對雙腔系統的強烈偏好，尤其是在高風險患者和老年患者中，以及其對多種傳導障礙的適應性，持續鞏固該細分市場的領先地位。

預計到2025年，心搏過緩市場規模將達29億美元。心搏過緩仍是植入式心臟節律器的主要臨床適應症。這是因為這些裝置已被廣泛接受為治療心搏過緩的標準療法。心搏過緩通常與心臟傳導系統的老齡化相關性退化、心血管疾病、藥物作用和自主神經功能障礙有關。患者常出現疲勞、頭暈、暈厥和呼吸困難等症狀，這些症狀會顯著降低患者的生活品質並增加心血管風險。植入式心臟節律器可透過可控刺激有效恢復正常心率，進而改善症狀控制並提升患者的整體預後。

預計到2025年，北美植入式心臟節律器市佔率將達到41.7%。該地區心血管疾病和心律不整相關疾病的高發生率是其市場主導地位的主要支撐因素，而這些疾病的發生又與人口老化、肥胖、高血壓、糖尿病以及生活方式相關的風險因素密切相關。技術的顯著進步進一步鞏固了該地區市場的地位，製造商不斷致力於無導線系統、核磁共振兼容設備、延長電池壽命以及遠端監測功能等領域的創新。

目錄

第1章：調查方法

  • 研究途徑
  • 品質改進計劃
    • GMI人工智慧政策和資料完整性計劃
      • 資訊來源一致性協議
  • 調查過程和可靠性評分
    • 調查過程的組成部分
    • 評分組成部分
  • 數據收集
    • 主要來源部分列表
  • 資料探勘資訊來源
    • 付費資訊來源
      • 區域資訊來源
  • 基本估算和計算方法
    • 每種方法中基準年的計算
  • 預測模型
    • 量化市場影響分析
      • 生長參數對預測的數學影響
  • 關於調查透明度的補充信息
    • 資訊來源歸屬框架
    • 品質保證指標
    • 對信任的承諾

第2章執行摘要

第3章業界考察

  • 生態系分析
  • 影響產業的因素
    • 促進因素
      • 心血管疾病盛行率上升和人口老化
      • 無導線和MRI相容設備的技術進步
      • 遠端監控和遠端醫療解決方案的廣泛應用
      • 有利的贖回方案
    • 產業潛在風險與挑戰
      • 植入式心臟節律器高成本
      • 風險與挑戰
    • 市場機遇
      • 擴大門診手術中心規模，以提供更具成本效益的手術
      • 人工智慧驅動的心率節律管理預測分析
  • 成長潛力分析
  • 監理情勢（基於初步調查）
  • 科技趨勢
    • 當前技術趨勢
    • 新興技術
  • 還款方案（基於初步調查）
  • 未來市場趨勢
  • 波特五力分析
  • PESTEL 分析
  • 專利分析（基於初步研究）
  • 價格分析（2025 年）（基於初步調查）
  • 投資與資金籌措分析
  • 供應鏈分析
  • 人工智慧和生成式人工智慧對市場的影響
    • 利用人工智慧改造現有經營模式
    • 按細分市場分類的生成式人工智慧用例和部署藍圖
    • 風險、限制和監管考量
  • 差距分析

第4章 競爭情勢

  • 介紹
  • 企業矩陣分析
  • 企業市佔率分析（基於初步研究）
    • 世界
    • 北美洲
    • 歐洲
    • 亞太地區
  • 競爭定位矩陣
  • 主要市場公司的競爭分析
  • 主要進展
    • 併購
    • 夥伴關係與合作
    • 新產品發布
    • 業務拓展計劃

第5章 市場估價與預測：依產品分類，2022-2035年

  • 單腔心律調節器
    • 單腔心房型
    • 單心室型
  • 雙腔心律調節器
  • 雙心室/CRT心律調節器

第6章 市場估計與預測：依應用領域分類，2022-2035年

  • 心搏過緩
  • 心律不整
  • 其他用途

第7章 市場估計與預測：依最終用途分類，2022-2035年

  • 醫院和診所
  • 心臟護理中心
  • 門診手術中心
  • 其他最終用戶

第8章 市場估計與預測：依地區分類，2022-2035年

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第9章：公司簡介

  • Abbott
  • BIOTRONIK
  • Boston Scientific
  • Lepu Medical
  • MEDICO
  • Medtronic
  • MicroPort
  • Shree Pacetronix
  • Vitatron
簡介目錄
Product Code: 9277

The Global Implantable Pacemakers Market was valued at USD 5.3 billion in 2025 and is estimated to grow at a CAGR of 4.8% to reach USD 8.3 billion by 2035.

Implantable Pacemakers Market - IMG1

The market is expanding due to the rising burden of cardiovascular diseases and the increasing adoption of minimally invasive cardiac procedures across healthcare systems worldwide. Growing preference for advanced cardiac rhythm management solutions, supported by favorable reimbursement frameworks, is further strengthening market adoption. Implantable pacemakers are medical devices designed to regulate abnormal heart rhythms by delivering controlled electrical impulses to maintain a stable heart rate. These devices continuously monitor cardiac electrical activity and intervene when irregularities occur, ensuring effective rhythm correction. The increasing incidence of atrial fibrillation and bradyarrhythmias is strongly linked to aging populations, sedentary behavior, obesity, diabetes, and poor dietary habits, all of which are becoming more prevalent globally. Expanding elderly populations are also contributing significantly to demand, as age-related conduction disorders such as atrioventricular block and sick sinus syndrome are becoming more common. As life expectancy rises, the need for long-term cardiac rhythm management solutions is expected to remain strong, supporting sustained market growth.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$5.3 Billion
Forecast Value$8.3 Billion
CAGR4.8%

The dual-chamber pacemakers segment held a share of 78.7% in 2025. This segment leads due to its ability to maintain atrioventricular synchrony, resulting in improved cardiac efficiency and better patient outcomes compared to single-chamber alternatives. Strong clinical preference for dual-chamber systems, particularly in high-risk and elderly patient populations, along with their suitability for a wide range of conduction disorders, continues to reinforce their market dominance.

The bradycardia segment accounted for USD 2.9 billion in 2025. Bradycardia remains a primary clinical indication for implantable pacemakers, as these devices are widely accepted as the standard treatment for managing slow heart rhythms. The condition is commonly associated with age-related degeneration of the cardiac conduction system, cardiovascular disorders, medication effects, and autonomic dysfunction. Patients often experience symptoms such as fatigue, dizziness, fainting episodes, and shortness of breath, which can significantly reduce quality of life and increase cardiovascular risk. Implantable pacemakers effectively restore normal heart rhythm through controlled stimulation, improving both symptom management and overall patient outcomes.

North America Implantable Pacemakers Market accounted for a 41.7% share in 2025. The region's leadership is supported by a high prevalence of cardiovascular and rhythm-related disorders driven by aging demographics, obesity, hypertension, diabetes, and lifestyle-related risk factors. Strong technological advancement further strengthens the regional market, with manufacturers continuously focusing on innovation in areas such as leadless systems, MRI-compatible devices, extended battery performance, and remote monitoring capabilities.

Key companies operating in the Global Implantable Pacemakers Industry include Abbott, BIOTRONIK, Boston Scientific, Lepu Medical, MEDICO, Medtronic, MicroPort, Shree Pacetronix, and Vitatron. Companies in the implantable pacemakers market are prioritizing continuous innovation in cardiac rhythm management technologies to improve device safety, longevity, and performance. Significant investments in research and development are enabling the introduction of miniaturized devices, leadless systems, and advanced monitoring capabilities. Strategic collaborations with hospitals and cardiac care centers are strengthening clinical adoption and expanding procedural access. Manufacturers are also focusing on enhancing battery efficiency and device durability to reduce replacement frequency and improve patient convenience. Expansion into emerging healthcare markets is supporting broader patient reach and revenue diversification.

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Research approach
  • 1.2 Quality commitments
    • 1.2.1 GMI AI policy & data integrity commitment
      • 1.2.1.1 Source consistency protocol
  • 1.3 Research trail & confidence scoring
    • 1.3.1 Research trail components
    • 1.3.2 Scoring components
  • 1.4 Data collection
    • 1.4.1 Partial list of primary sources
  • 1.5 Data mining sources
    • 1.5.1 Paid sources
      • 1.5.1.1 Sources, by region
  • 1.6 Base estimates and calculations
    • 1.6.1 Base year calculation for any one approach
  • 1.7 Forecast model
    • 1.7.1 Quantified market impact analysis
      • 1.7.1.1 Mathematical impact of growth parameters on forecast
  • 1.8 Research transparency addendum
    • 1.8.1 Source attribution framework
    • 1.8.2 Quality assurance metrics
    • 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product trends
    • 2.2.3 Application trends
    • 2.2.4 End use trends
  • 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of cardiovascular diseases & aging demographics
      • 3.2.1.2 Technological advancements in leadless and MRI-compatible devices
      • 3.2.1.3 Growing adoption of remote monitoring and telehealth solutions
      • 3.2.1.4 Favorable reimbursement scenario
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of implantable pacemakers
      • 3.2.2.2 Risks and complications
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expansion of ambulatory surgical centers for cost-effective procedures
      • 3.2.3.2 AI-enabled predictive analytics for cardiac rhythm management
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape (Driven by primary research)
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
    • 3.4.4 Latin America
    • 3.4.5 Middle East and Africa
  • 3.5 Technology landscape
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Reimbursement scenario (Driven by primary research)
  • 3.7 Future market trends
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis
  • 3.10 Patent analysis (Driven by primary research)
  • 3.11 Pricing analysis, 2025 (Driven by primary research)
  • 3.12 Investment and funding analysis
  • 3.13 Supply chain analysis
  • 3.14 Impact of AI and Generative AI on the market
    • 3.14.1 AI-driven disruption of existing business models
    • 3.14.2 GenAI use cases and adoption roadmap by segment
    • 3.14.3 Risks, limitations and regulatory considerations
  • 3.15 Gap analysis

Chapter 4 Competitive Landscape, 2025

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis (Driven by primary research)
    • 4.3.1 Global
    • 4.3.2 North America
    • 4.3.3 Europe
    • 4.3.4 Asia Pacific
  • 4.4 Competitive positioning matrix
  • 4.5 Competitive analysis of major market players
  • 4.6 Key developments
    • 4.6.1 Mergers & acquisitions
    • 4.6.2 Partnerships & collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

  • 5.1 Key trends
  • 5.2 Single-chamber pacemakers
    • 5.2.1 Single-chamber atrial
    • 5.2.2 Single-chamber ventricular
  • 5.3 Dual-chamber pacemakers
  • 5.4 Biventricular/CRT pacemakers

Chapter 6 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

  • 6.1 Key trends
  • 6.2 Bradycardia
  • 6.3 Arrhythmias
  • 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals & clinics
  • 7.3 Cardiac care centers
  • 7.4 Ambulatory surgical centers
  • 7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Abbott
  • 9.2 BIOTRONIK
  • 9.3 Boston Scientific
  • 9.4 Lepu Medical
  • 9.5 MEDICO
  • 9.6 Medtronic
  • 9.7 MicroPort
  • 9.8 Shree Pacetronix
  • 9.9 Vitatron